The potential shared indications forCB1 and CB2 agonists include pain,24 anxiety,25 neurodegenerative disorders,26 cancer,27 emesis, and nausea.28 Of note, there are some conditions such as addiction,29 systemic sclerosis,30 atherosclerosis,31 obesity,32 or diabetes,33 whereCB1 antagonists can be successfully replaced with CB2 agonists withoutseriously compromising the therapeutic outcome. This evidence concerns the gene CNR2 and systemic sclerosis.